Compare Citra Marga Nusaphala Persada Tbk. (CMNP) vs Medela Potentia Tbk. (MDLA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citra Marga Nusaphala Persada Tbk. vs Medela Potentia Tbk. — how do they compare? Citra Marga Nusaphala Persada Tbk. trades at Rp1,345 (market cap 9.11T, 96.2K 24h volume), while Medela Potentia Tbk. trades at Rp206 (market cap 2.91T, 383.3K 24h volume). The key difference: Citra Marga Nusaphala Persada Tbk. is far larger — about 3.1× Medela Potentia Tbk.'s market cap, and Medela Potentia Tbk. is more actively traded (383.3K versus 96.2K). Which is the better fit depends on your goals.
| CMNP | MDLA | |
|---|---|---|
Market Cap | 9.11T | 2.91T |
Volume | 96.2K | 383.3K |
Lot | 962 | 3.83K |
Turnover | 129.18M | 79.26M |
Average Price | 1,342.87 | 206.79 |
Value | 129.18M | 79.26M |
Indicative Equilibrium Price | 1,345 | 206 |
Indicative Equilibrium Volume | 2 | 150 |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Citra Marga Nusaphala Persada Tbk.
PT Citra Marga Nusaphala Persada Tbk (the Company) was established within the framework of the Domestic Investment Law No. 6 of 1968, as amended by Law No. 12 of 1970 based on Notarial Deed No. 58 dated April 13, 1987 of Kartini Muljadi, S.H.The Company derives its revenues primarily from tollgate proceeds, project management fees and, to a lesser extent, from services related to the operations of a toll way system. The Company started commercial operations on March 1990. On June 19th, 1996, the Tanjung Priok – Jembatan Tiga toll road started commercial operations.
Read more on CMNP →About Medela Potentia Tbk.
PT Medela Potentia Tbk. (Company) was established based on Deed of Establishment No. 04 dated August 5, 2011, of Public Notary Evy Ferdiana, S.H, Notary of Bekasi Regency, domiciled in Lemah Abang. The Company started its operation activities in 2013.
Read more on MDLA →
